<DOC>
	<DOCNO>NCT01086033</DOCNO>
	<brief_summary>The objective study observe ass long-term use , safety efficacy Humira ( adalimumab ) , prescribed rheumatologist normal clinical set accordance term European marketing authorization observe compliance patient prescribe treatment .</brief_summary>
	<brief_title>A 3-year Study Following Patients With Moderate Severe Rheumatoid Arthritis Treated With Humira Greece</brief_title>
	<detailed_description>This multi-center , uncontrolled observational study patient time entry moderate severe rheumatoid arthritis ( RÎ‘ ) subsequently prescribe Humira ( adalimumab ) follow normal clinical practice , without anti-rheumatic treatment , prior enrollment study . Once physician determine patient meet inclusion criterion , patient agree include observational study signing informed consent , patient 's Day 1 demographic data , disease status report Day 1 Data Report Forms . The physician follow-up patient via regular office visit interval determine routine clinical practice . Patient 's safety efficacy data , part clinical routine , record Data Report Forms Day 1 , regular visit closest Month 3 , Month 6 , Month 9 , Month 12 , Month 18 , Month 24 , Month 30 , Month 36 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients moderate severe active rheumatoid arthritis , prescribe receive Humira ( adalimumab ) normal clinical practice least one month prior inclusion accord approve Summary Product Characteristics ( SPC ) European Union . Patients must willing consent data collect provided Abbott Laboratories . Contraindications accord SPC . Patients participate another observational Abbott study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Evaluation safety efficacy</keyword>
	<keyword>Adalimumab treatment</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>